Markus Moehler - Researcher Profile | RDL Research Database

Publications

3 shown

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

2021 The Lancet 2580 citations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

2019 The Lancet 2355 citations

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly , Jaffer A. Ajani , Jarosław Kużdżał +24 more

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among ...

2021 New England Journal of Medicine 1584 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 6,519
Institution: Johannes Gutenberg University Mainz

External Links

Google Scholar

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.